To explore the evolution of therapeutic goals in inflammatory bowel disease (IBD) and the critical need for effective disease-modifying therapies.
Key Findings:
Mucosal healing is now a primary endpoint in IBD management.
Most IBD trials focus on short- to medium-term outcomes rather than long-term disease modification, limiting their applicability.
Early intervention with anti-TNF therapies has shown promise in reducing complications, but more evidence is needed.
Interpretation:
While advances in IBD therapies are notable, the field lacks robust evidence for disease-modifying treatments, highlighting an urgent need for further research.
Limitations:
Challenges in obtaining long-term randomized data on IBD therapies.
High costs and time requirements make disease-modification trials a low priority for sponsors.
Increased exposure to advanced therapies complicates the assessment of new drugs and their potential for disease modification.
Conclusion:
Collaboration within the IBD community is essential to conduct high-quality research that can clarify the long-term effects of therapies on disease progression and to prioritize disease-modifying research.
Keck Medicine of USC gastroenterologist Florence-Damilola (Damie) Odufalu, MD, shares how recent advances in inflammatory bowel disease treatment are changing the lives of patients.
